Thu, 5 Nov
Marksans Pharma
Headline growth is strong: revenue up 30.5% to ₹940 Cr and EBITDA margin 22.8%, above the 21–22% guide. Sequentially, margin, gross margin and PAT all fell, and growth is partly acquired.
Summary ready
Earnings calls
Marksans Pharma concalls
Every Marksans Pharma earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Headline growth is strong: revenue up 30.5% to ₹940 Cr and EBITDA margin 22.8%, above the 21–22% guide. Sequentially, margin, gross margin and PAT all fell, and growth is partly acquired.
Outlook
Targets ₹5,000 Cr revenue in three years and about ₹6,000 Cr in five. US order book target is about $300M within three years.
Earlier call summaries
All →
18:38 IST
NSE
Earnings Call
Marksans Pharma Earnings Call Transcript: Key Takeaways
Marksans Pharma delivered record FY26 results, crossing INR 3,000 Cr net income with 20.4% EBITDA margins. Management strategy focuses on diversification across US, UK, and Europe markets with high cash generation.
- Call
- Guides 20% growth
14:23 IST
BSE
Earnings Call
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma delivered record FY26 performance, crossing ₹3,000cr net income with highest-ever profitability. Strategy focuses on geographic diversification (US, UK, Australia) and transitioning to branded prescription generics.
18:52 IST
BSE
Earnings Call
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma reported record Q3 FY26 revenue of ₹754cr (up 10.6% YoY) with EBITDA margins expanding to 21.3%. Strategy focuses on UK/US market expansion and new launches.
13:28 IST
NSE
Earnings Call
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma achieved milestone FY26 performance with total income of ₹3,033 cr and record PAT of ₹420 cr. Strategy focuses on global OTC leadership and Rx expansion in Australia.
12:48 IST
NSE
Earnings Call
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma reported record Q3 FY26 revenue of ₹754cr (up 10.6% YoY) with EBITDA margins expanding to 21.3%. Strategy focuses on U.S. OTC and U.K. growth.
Marksans Pharma Ltd: key numbers
- Share price
- ₹303.70
- Market cap
- ₹13,764 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 24.6×Sector 43.0×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.